Moberg Pharma: Question marks straightened out, but uncertainty about approval in the US remains

Research Note

2020-01-23

11:42

The expert evaluation of the MOB-015 North American Phase 3 study results, presented yesterday, provides a credible explanation of why the complete cure data (primary endpoint) was surprisingly weak, meanwhile, the data of mycological cure was impressively strong. A solution to the problem is also suggested, but that would require a new clinical trial.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.